Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
COVID-19-related demand for test kits propelled a 23% jump in Abbott's ( ABT -0.2% ) U.S. diagnostics business to $857M last quarter. More news on: Abbott Laboratories, Danaher Corporation, Roche Holding AG, Healthcare stocks news, Read more ...
July 15, 2020 FN Media Group Presents USA News Group News Commentary Vancouver, BC – July 15, 2020 – USA News Group – A recent study from the National Comprehensive Cancer Center (NCCN) delivered a shocking indictment of the oncology field as a...
uniQure (QURE) is pivoting after securing a solid revenue stream through a licensing deal. Management is building shareholder value by advancing their early-stage pipeline and making a bet on AMT-130 which will handsomely reward shareholders if they prove successful in developing the first gen...
Quick Take Renalytix AI ( RNLX ) intends to raise $156 million from the sale of ADSs in an IPO, according to an amended registration statement . The company provides kidney function diagnostics services. RNLX has a promising business and market, but I can’t determine whether the ...
Quick Take Pandion Therapeutics ( PAND ) intends to raise $93.5 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatments for serious gastrointestinal and liver immune diseases. PAND is in Phase 1 trials fo...
Building on their 2016 partnershi p aimed at developing up to five kinase inhibitors in cancer, Roche ( OTCQX:RHHBY ) and Blueprint Medicines (NASDAQ: BPMC ) ink a new license and collaboration agreement to develop and commercialize RET inhibitor pralsetinib. More news on: Roche Hol...
Immunomedics (NASDAQ: IMMU ) will extend its clinical collaboration with Roche ( OTCQX:RHHBY ) with two new clinical trials evaluating the combination of anti-Trop-2 antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) and Tecentriq (atezolizumab) in bladder and lung cancer ...
Quick Take ALX Oncology ( ALXO ) intends to raise $128 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for various blood and solid tumor cancer conditions. ALXO is pursuing treatments in...
Roche ( OTCQX:RHHBY +0.6% ) unit Spark Therapeutics reports updated data from three dose cohorts in a Phase 1/2 clinical trial evaluating gene therapy candidate SPK-8011 in hemophilia A patients. The results were presented virtually at the International Society of Thrombosis and H...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP r...
– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70...